Adcendo raises $135m as ADC funding frenzy continues

Denmark's Adcendo, a biotech firm, secures $135m in funding to advance its antibody-drug conjugate (ADC) candidates. The company's lead ADC, ADCE-D01, targets soft tissue sarcoma.